FosterNC, MillerKM, DiMeglioLA, et al.: State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther, 2019; 21:66–72.
2.
DavisAK, DuBoseSN, HallerMJ, et al.: Prevalence of detectable c-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care, 2015; 38:476–481.
3.
ChaytorNS, RiddleswothTD, BzdickS, et al.: The relationship between neuropsychological assessment, numeracy, and functional status in older adults with type 1 diabetes. Neuropsychol Rehabil, 2017; 27:507–521.
4.
DuBoseSN, WeinstockRS, BeckRW, et al.: Hypoglycemia in older adults with type 1 diabetes (T1D). Diabetes Technol Ther, 2016; 18:765–771.
5.
WeinstockRS, DuBoseSN, BergenstalRM, et al.: Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes. Diabetes Care, 2016; 39:603–610.
6.
LibmanIM, MillerKM, DiMeglioLA, et al.: Effects of metformin added to insulin glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA, 2015; 314:2241–2250.
7.
AleppoG, RuedyKJ, RiddlesworthTD, et al.: REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in well-controlled adults with type 1 diabetes. Diabetes Care, 2017; 40:538–545.
8.
RickelsMR, RuedyKJ, FosterNC, et al.: Intranasal glucagon for treatment of insulin induced hypoglycemia in adults with type 1 diabetes: a randomized, cross-over non-inferiority study. Diabetes Care, 2016; 39:264–270.
9.
SherrJL, RuedyKJ, FosterNC, et al.: Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care, 2016; 39:555–562.
10.
HaymondMW, DuBoseSN, RickelsMR, et al.: Efficacy and safety of mini-dose glucagon for treatment of nonsevere hypoglycemia in adults with type 1 diabetes. JCEM, 2017; 102:2994–3001.
11.
RickelsMR, DuBoseSN, ToschiE, et al.: Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes. Diabetes Care, 2018; 41:1909–1916.
12.
BergenstalRM, GalRL, ConnorCG, et al.: Racial differences in the relationship of glucose concentrations and HbA1c levels. Ann Intern Med, 2017; 167:95–102.
13.
RiddlesworthTD, BeckRW, GalRL, et al.: Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. Diabetes Technol Ther, 2018; 20:1–3.
